Cambium Bio Limited has released a press release.
Cambium Bio: Notice of General Meeting/Proxy Form
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Response to ASX Aware Query
- Cambium Bio Raises A$3.48 Million in Strategic Placement
- Regeneus Completes the Merger with Cambium
- Half Yearly Report and Accounts
- Regeneus enters into binding merger agreement with Cambium
Later from Cambium Bio
- Cambium 4E and Annual Report
- Trading Halt
- Cambium Bio Successfully Closes A$3.0M Financing Round
- FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
- Half Year Report (December 2024)Cambium Bio Limited Half Year Report (December 2024) (Feb 27, 2025Feb 27, 2025)
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio